Wacker Biotech, a CDMO, began a strategic collaboration with Boston-based RNAV8 Bio aimed at progressing the development and production of mRNA-based advanced therapies for the biopharma industry.
In vitro-transcribed mRNAs have been proven efficient in various therapeutic applications. However, manufacturing them poses challenges due in part to complexity of the molecules as well as the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback